2.94% -0.1019

Neximmune Inc (NEXI)

개요 뉴스 가격 이력 Financials 토론 예측 주식 분할

Relative Volume:

Neximmune Inc Stock (NEXI) Company Profile

Neximmune Inc

Healthcare (1171)

Biotechnology (661)

최신 SEC 제출 서류

NEXI's Discussions on Twitter

NEXI을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
NEXI Neximmune Inc	0.00	0	0	-20.62M	-17.61M	-18.54
VRTX Vertex Pharmaceuticals Inc	444.31	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	519.21	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	319.85	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	561.10	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	261.73	28.51B	3.81B	-644.79M	-669.77M	-6.24

Neximmune Inc Stock (NEXI) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2021-04-01	개시	Raymond James	Outperform
2021-03-09	개시	Barclays	Overweight
2021-03-09	개시	Cantor Fitzgerald	Overweight

Neximmune Inc 주식(NEXI)의 최신 뉴스

Neximmune Inc (NEXI) 재무 분석

Neximmune Inc (NEXI)

Neximmune Inc Stock (NEXI) Company Profile

NEXI을(를) 다른 주식과 비교

Neximmune Inc Stock (NEXI) Upgrades & Downgrades

Neximmune Inc 주식(NEXI)의 최신 뉴스

Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com

Analyzing Theratechnologies (NASDAQ:THTX) and NexImmune (NASDAQ:NEXI) - Defense World

TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve

Vanotech Appoints Matthew Schiller to Lead Business Development - citybiz

Vanotech appoints Matthew Schiller to Lead Business Development - EFECOMUNICA

Reviewing NexImmune (NASDAQ:NEXI) & Benitec Biopharma (NASDAQ:BNTC) - Defense World

NexImmune (NASDAQ:NEXI) Stock Price Down 15.2% – Should You Sell? - Defense World

North American Morning Briefing : Tesla, Chip -2- -January 03, 2025 at 06:08 am EST - Marketscreener.com

U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.76% - MSN

Immunomodulators Market Size to Worth Around US$ 1,237.66 Bn by 2033 - BioSpace

NexImmune moves forward with wind-down process - The Business Journals

NexImmune shareholders approve company dissolution - Investing.com

What Are the Rules Behind the Delisting of a Stock? - Investopedia

NEXI Stock Alert: NexImmune Delists From Nasdaq - InvestorPlace

What Is Going on With NexImmune (NEXI) Stock Today? - InvestorPlace

Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Yahoo Finance

Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com

NexImmune Faces Critical Funding Crisis, Mulls Liquidation - TipRanks

NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation - InvestorPlace

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga

NexImmune's future in limbo as Gaithersburg biotech extends liquidation vote - The Business Journals

NEXI Stock Halted: What’s Going on With NexImmune Shares Today? - InvestorPlace

Gaithersburg’s NexImmune prepares to shut down, lay off ‘substantially all’ employees - The Business Journals

Rockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from Nasdaq - The Business Journals

D.C.'s Vanda Pharmaceuticals to ask Supreme Court to review patent infringement lawsuit - The Business Journals

NexImmune (NASDAQ: NEXI) to jump 2,500% todaya purely technical move - Dhaka Tribune

NexImmune to lay off over half of its employees - Pharmaceutical Technology

NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy - Stock Titan

An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT). - ASCO Publications

Sirnaomics spinout RNAImmune launching clinical trial for Covid-19 vaccine booster - The Business Journals

Gaithersburg biotech Salubris Biotherapeutics clinches $35M investment for R&D - The Business Journals

Silver Spring's Aziyo Biologics laying off 12% of workforce - The Business Journals

Why NexImmune (NEXI) Shares Are Trading Higher TodayNexImmune (OTC:NEXI) - Benzinga

Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’ - insights.citeline.com

AIM™ platform: A new immunotherapy approach for viral diseases - Frontiers

Biotechs reveal layoffs, research revamps in third quarter earnings - BioPharma Dive

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders - Business Wire

Refractory Multiple Myeloma Pipeline Analysis of 80+ therapies: Key Pharma Players Set to Develop Novel Therapies - GlobeNewswire

Global Human Papillomavirus Associated Cancer Pipeline - GlobeNewswire

Zephyr AI Announces Additions to the Board of Directors - Business Wire

Pharma50: 50 Leading Cell and Gene Therapy Companies - drugdiscoverytrends.com

What Makes NexImmune, Inc. (NEXI) a New Buy Stock - Nasdaq

NexImmune Appoints Dr. Leena Gandhi To Board - citybiz

NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer - The Globe and Mail

D.C. Council member ends effort to reinstate proof of vaccination requirement to enter businesses - The Business Journals

NexImmune Appoints Kristi Jones as CEO - citybiz

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product - Business Wire

It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits. - The Business Journals

Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Program - Business Wire

Neximmune Inc (NEXI) 재무 분석

매출

순이익

현금흐름

주당 순 이익

NEXI과 유사한 종목